PUBLICACIONES DE LOS ÚLTIMOS 10 AÑOS

Publicaciones de los últimos 10 años del Laboratorio de Neurociencias del ICC

2020

  1. Calfio C, Gonzalez A, Singh SK, Rojo LE, Maccioni RB. The Emerging Role of Nutraceuticals and Phytochemicals in the Prevention and Treatment of Alzheimer’s J Alzheimers Dis. 2020;77(1):33-51. doi: 10.3233/JAD-200443.

    2.  

  2. Maccioni RB, Navarrete LP, González A, González-Canacer A, Guzmán-Martínez L, Cortés N. Inflammation: A Major Target for Compounds to Control Alzheimer’s Disease. J Alzheimers Dis. 2020;76(4):1199-1213. doi: 10.3233/JAD-191014.

    3.  

  3. Andrade V, Cortés N, Pastor G, Gonzalez A, Ramos-Escobar N, Pastene E, Rojo LE, Maccioni RB. N-Acetyl Cysteine and Catechin-Derived Polyphenols: A Path Toward Multi-Target Compounds Against Alzheimer’s Disease. J Alzheimers Dis. 2020;75(4):1219-1227. doi: 10.3233/JAD-200067.

    4.  

  4. González A, Guzmán-Martínez L, Maccioni RB. Plasma Tau Variants Detected by a Novel Anti-Tau Monoclonal Antibody: A Potential Biomarker for Alzheimer’s Disease. J Alzheimers Dis. 2020;77(2):877-883. doi: 10.3233/JAD-200386.

2019

  1. Guzman-Martinez L, Maccioni RB, Andrade V, Navarrete LP, Pastor MG, Ramos-Escobar N. Neuroinflammation as a Common Feature of Neurodegenerative Disorders. Front Pharmacol. 2019 Sep 12;10:1008. doi: 10.3389/fphar.2019.01008. eCollection 2019.

    2.  

  2. Guzman-Martinez L, Maccioni RB, Farías GA, Fuentes P, Navarrete LP. Biomarkers for Alzheimer’s Disease. Curr Alzheimer Res. 2019;16(6):518-528. doi: 10.2174/1567205016666190517121140.

    3.  

  3. Cortés N, Guzmán-Martínez L, Andrade V, González A, Maccioni RB. CDK5: A Unique CDK and Its Multiple Roles in the Nervous System. J Alzheimers Dis. 2019;68(3):843-855. doi: 10.3233/JAD-180792.

    4.  

  4. Guzmán-Martínez L, Tapia JP, Farías GA, González A, Estrella M, Maccioni RB. The Alz-tau Biomarker for Alzheimer’s Disease: Study in a Caucasian Population. J Alzheimers Dis. 2019;67(4):1181-1186. doi: 10.3233/JAD-180637.

2018

  1. Maccioni RB, González A, Andrade V, Cortés N, Tapia JP, Guzmán-Martínez L. Alzheimer´s Disease in the Perspective of Neuroimmunology. Open Neurol J. 2018 Jun 29;12:50-56. doi: 10.2174/1874205X01812010050. eCollection 2018.

    2.  

  2. Cortés N, Andrade V, Maccioni RB. Behavioral and Neuropsychiatric Disorders in Alzheimer’s Disease. J Alzheimers Dis. 2018;63(3):899-910. doi: 10.3233/JAD-180005.

    3.  

  3. Cortés N, Andrade V, Guzmán-Martínez L, Estrella M, Maccioni RB. Neuroimmune Tau Mechanisms: Their Role in the Progression of Neuronal Degeneration. Int J Mol Sci. 2018 Mar 23;19(4):956. doi: 10.3390/ijms19040956.

    4.  

  4. Maccioni RB, Tapia JP, Guzman-Martinez L. Pathway to Tau Modifications and the Origins of Alzheimer’s Disease. Arch Med Res. 2018 Feb;49(2):130-131. doi:10.1016/j.arcmed.2018.05.002.

2017

  1. Morales I, Cerda-Troncoso C, Andrade V, Maccioni RB. The Natural Product Curcumin as a Potential Coadjuvant in Alzheimer’s Treatment. J Alzheimers Dis. 2017;60(2):451-460. doi: 10.3233/JAD-170354.

    2.  

  2. Slachevsky A, Guzmán-Martínez L, Delgado C, Reyes P, Farías GA, Muñoz-Neira C, Bravo E, Farías M, Flores P, Garrido C, Becker JT, López OL, Maccioni RB. Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2017;55(4):1595-1603. doi: 10.3233/JAD-160652.

2014

    1. Farías GA, Guzmán-Martínez L, Delgado C, Maccioni RB. Nutraceuticals: a novel concept in prevention and treatment of Alzheimer’s disease and related disorders. J Alzheimers Dis. 2014;42(2):357-67. doi: 10.3233/JAD-132741.

 

  1. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer’s disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci. 2014 Apr 22;8:112. doi: 10.3389/fncel.2014.00112. eCollection 2014.

2013

    1. Guzmán-Martinez L, Farías GA, Maccioni RB. Tau oligomers as potential targets for Alzheimer’s diagnosis and novel drugs. Front Neurol. 2013 Oct 28;4:167. doi: 10.3389/fneur.2013.00167.

 

  1. Morales I, Jiménez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis. 2013;37(4):849-56. doi: 10.3233/JAD-131843.

2012

  1. Maccioni RB. Introductory remarks. Molecular, biological and clinical aspects of Alzheimer’s disease. Arch Med Res. 2012 Nov;43(8):593-4. doi: 10.1016/j.arcmed.2012.11.001.

    2.  

  2. Guzmán-Martínez L, Farías GA, Maccioni RB. Emerging noninvasive biomarkers for early detection of Alzheimer’s disease. Arch Med Res. 2012 Nov;43(8):663-6. doi: 10.1016/j.arcmed.2012.10.013.

    3.  

  3. Carrasco-Gallardo C, Farías GA, Fuentes P, Crespo F, Maccioni RB. Can nutraceuticals prevent Alzheimer’s disease? Potential therapeutic role of a formulation containing shilajit and complex B vitamins. Arch Med Res. 2012 Nov;43(8):699-704. doi: 10.1016/j.arcmed.2012.10.010.

    4.  

  4. Carrasco-Gallardo C, Guzmán L, Maccioni RB. Shilajit: a natural phytocomplex with potential procognitive activity. Int J Alzheimers Dis. 2012;2012:674142. doi: 10.1155/2012/674142.

    5.  

  5. Farías G, Pérez P, Slachevsky A, Maccioni RB. Platelet tau pattern correlates with cognitive status in Alzheimer’s disease. J Alzheimers Dis. 2012;31(1):65-9. doi: 10.3233/JAD-2012-120304.

    6.  

  6. Navarrete LP, Guzmán L, San Martín A, Astudillo-Saavedra L, Maccioni RB. Molecules of the quinoline family block tau self-aggregation: implications toward a therapeutic approach for Alzheimer’s disease. J Alzheimers Dis. 2012;29(1):79-88. doi: 10.3233/JAD-2011-110995.

    7.  

  7. Mendoza-Naranjo A, Contreras-Vallejos E, Henriquez DR, Otth C, Bamburg JR, Maccioni RB, Gonzalez-Billault C. Fibrillar amyloid-β1-42 modifies actin organization affecting the cofilin phosphorylation state: a role for Rac1/cdc42 effector proteins and the slingshot phosphatase. J Alzheimers Dis. 2012;29(1):63-77. doi: 10.3233/JAD-2012-101575.

2011

  1. Maccioni RB. Tau protein in Alzheimer’s disease. Curr Alzheimer Res. 2011 Sep;8(6):607. doi: 10.2174/156720511796717159.

    2.  

  2. Farías G, Cornejo A, Jiménez J, Guzmán L, Maccioni RB. Mechanisms of tau self-aggregation and neurotoxicity. Curr Alzheimer Res. 2011 Sep;8(6):608-14. doi: 10.2174/156720511796717258.

    3.  

  3. Navarrete LP, Pérez P, Morales I, Maccioni RB. Novel drugs affecting tau behavior in the treatment of Alzheimer’s disease and tauopathies. Curr Alzheimer Res. 2011 Sep;8(6):678-85. doi: 10.2174/156720511796717122.

    4.  

  4. Rojo LE, Gaspar PA, Maccioni RB. Molecular targets in the rational design of AD specific PET tracers: tau or amyloid aggregates? Curr Alzheimer Res. 2011 Sep;8(6):652-8. doi: 10.2174/156720511796717203.

    5.  

  5. Neumann K, Farías G, Slachevsky A, Perez P, Maccioni RB. Human platelets tau: a potential peripheral marker for Alzheimer’s disease. J Alzheimers Dis. 2011;25(1):103-9. doi: 10.3233/JAD-2011-101641.

    6.  

  6. Cornejo A, Jiménez JM, Caballero L, Melo F, Maccioni RB. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer’s disease. J Alzheimers Dis. 2011;27(1):143-53. doi: 10.3233/JAD-2011-110623.

2010

  1. Morales I, Farías G, Maccioni RB. Neuroimmunomodulation in the pathogenesis of Alzheimer’s disease. 2010;17(3):202-4. doi: 10.1159/000258724.

    2.  

  2. Maccioni RB, Farías G, Morales I, Navarrete L. The revitalized tau hypothesis on Alzheimer’s disease. Arch Med Res. 2010 Apr;41(3):226-31. doi: 10.1016/j.arcmed.2010.03.007.

    3.  

  3. Zambrano A, Otth C, Maccioni RB, Concha II. IL-3 controls tau modifications and protects cortical neurons from neurodegeneration. Curr Alzheimer Res. 2010 Nov;7(7):615-24. doi: 10.2174/156720510793499011.

    4.  

  4. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB. Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer’s disease. J Alzheimers Dis. 2010;19(2):573-89. doi: 10.3233/JAD-2010-1262.